Zobrazeno 1 - 10
of 171
pro vyhledávání: '"Tohru Mochizuki"'
Autor:
Takeshi Nagashima, Ken Yamaguchi, Kenichi Urakami, Yuji Shimoda, Sumiko Ohnami, Keiichi Ohshima, Tomoe Tanabe, Akane Naruoka, Fukumi Kamada, Masakuni Serizawa, Keiichi Hatakeyama, Shumpei Ohnami, Koji Maruyama, Tohru Mochizuki, Maki Mizuguchi, Akio Shiomi, Yasuhisa Ohde, Etsuro Bando, Teiichi Sugiura, Takashi Mukaigawa, Seiichiro Nishimura, Yasuyuki Hirashima, Koichi Mitsuya, Shusuke Yoshikawa, Yoshio Kiyohara, Yasuhiro Tsubosa, Hirohisa Katagiri, Masashi Niwakawa, Kaoru Takahashi, Hiroya Kashiwagi, Yoshichika Yasunaga, Yuji Ishida, Takashi Sugino, Hirotsugu Kenmotsu, Masanori Terashima, Mitsuru Takahashi, Katsuhiko Uesaka, Yasuto Akiyama
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract In cancer genome analysis, identifying pathogenic alterations and assessing their effects on oncogenic processes is important. Although whole exome sequencing (WES) can effectively detect such changes, driver alterations could not be identif
Externí odkaz:
https://doaj.org/article/78e02debd67d4858aa07bf66640f5372
Autor:
Keiichi Hatakeyama, Koji Muramatsu, Takeshi Nagashima, Yuichi Kawanishi, Ryutaro Fukumura, Keiichi Ohshima, Yuji Shimoda, Hirotsugu Kenmotsu, Tohru Mochizuki, Kenichi Urakami, Yasuto Akiyama, Takashi Sugino, Ken Yamaguchi
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-8 (2022)
Abstract Targeted sequencing offers an opportunity to select specific drugs for cancer patients based on alterations in their genome. However, accurate sequencing cannot be performed in cancers harboring diffuse tumor cells because of low tumor conte
Externí odkaz:
https://doaj.org/article/6695e80cba474b6392ca70861efa1b00
Autor:
Keiichi Hatakeyama, Takeshi Nagashima, Akifumi Notsu, Keiichi Ohshima, Sumiko Ohnami, Shumpei Ohnami, Yuji Shimoda, Akane Naruoka, Koji Maruyama, Akira Iizuka, Tadashi Ashizawa, Hirotsugu Kenmotsu, Tohru Mochizuki, Kenichi Urakami, Yasuto Akiyama, Ken Yamaguchi
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-7 (2021)
Abstract Background Mutation analysis using next-generation sequencing highlights the features of tumors with somatic alterations. However, the mutation profile of double cancer remains unclear. Here, we analyzed tumors derived from the same patient
Externí odkaz:
https://doaj.org/article/c6e030458494413aafb8ee252b5ac89a
Autor:
Keiichi Ohshima, Keiichi Hatakeyama, Takeshi Nagashima, Yuko Watanabe, Kaori Kanto, Yuki Doi, Tomomi Ide, Yuji Shimoda, Tomoe Tanabe, Sumiko Ohnami, Shumpei Ohnami, Masakuni Serizawa, Koji Maruyama, Yasuto Akiyama, Kenichi Urakami, Masatoshi Kusuhara, Tohru Mochizuki, Ken Yamaguchi
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-13 (2017)
Abstract Identification of driver genes contributes to the understanding of cancer etiology and is imperative for the development of individualized therapies. Gene amplification is a major event in oncogenesis. Driver genes with tumor-specific amplif
Externí odkaz:
https://doaj.org/article/e4035a2588bc4f009de6291a94d531c3
Autor:
Keiichi Ohshima, Kanako Inoue, Akemi Fujiwara, Keiichi Hatakeyama, Kaori Kanto, Yuko Watanabe, Koji Muramatsu, Yorikane Fukuda, Shun-ichiro Ogura, Ken Yamaguchi, Tohru Mochizuki
Publikováno v:
PLoS ONE, Vol 5, Iss 10, p e13247 (2010)
BackgroundExosomes play a major role in cell-to-cell communication, targeting cells to transfer exosomal molecules including proteins, mRNAs, and microRNAs (miRNAs) by an endocytosis-like pathway. miRNAs are small noncoding RNA molecules on average 2
Externí odkaz:
https://doaj.org/article/8d52301de72b403c969d56b6e6c29048
Autor:
Yuji, Shimoda, Takeshi, Nagashima, Kenichi, Urakami, Fukumi, Kamada, Sou, Nakatani, Maki, Mizuguchi, Masakuni, Serizawa, Keiichi, Hatakeyama, Keiichi, Ohshima, Tohru, Mochizuki, Sumiko, Ohnami, Shumpei, Ohnami, Takeshi, Kawakami, Kentaro, Yamazaki, Haruyasu, Murakami, Hirotsugu, Kenmotsu, Akio, Shiomi, Yasuto, Akiyama, Ken, Yamaguchi
Publikováno v:
Biomedical Research. 43:115-126
Next-generation sequencing (NGS) is an integral part of precision medicine, and its power for detecting comprehensive genetic alterations may contribute to treatment decisions for patients with advanced, recurrent, or metastatic cancer. An NGS oncolo
Autor:
Yasuto Akiyama, Akifumi Notsu, Tadashi Ashizawa, Tohru Mochizuki, Yuji Shimoda, Keiichi Hatakeyama, Shumpei Ohnami, Hirotsugu Kenmotsu, Koji Maruyama, Sumiko Ohnami, Ken Yamaguchi, Akane Naruoka, Keiichi Ohshima, Kenichi Urakami, Takeshi Nagashima, Akira Iizuka
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-7 (2021)
BMC Cancer
BMC Cancer
Background Mutation analysis using next-generation sequencing highlights the features of tumors with somatic alterations. However, the mutation profile of double cancer remains unclear. Here, we analyzed tumors derived from the same patient using who
Autor:
Keiichi Hatakeyama, Koji Muramatsu, Takeshi Nagashima, Yuichi Kawanishi, Ryutaro Fukumura, Keiichi Ohshima, Yuji Shimoda, Hirotsugu Kenmotsu, Tohru Mochizuki, Kenichi Urakami, Yasuto Akiyama, Takashi Sugino, Ken Yamaguchi
Publikováno v:
Scientific reports. 12(1)
Targeted sequencing offers an opportunity to select specific drugs for cancer patients based on alterations in their genome. However, accurate sequencing cannot be performed in cancers harboring diffuse tumor cells because of low tumor content. We pe
Autor:
Masakuni Serizawa, Akio Shiomi, Keiichi Hatakeyama, Yasuto Akiyama, Keiichi Ohshima, Masatoshi Kusuhara, Kenichi Urakami, Sumiko Ohnami, Yasuhiro Tsubosa, Ken Yamaguchi, Takeshi Nagashima, Yuko Watanabe, Akane Naruoka, Yuji Shimoda, Tohru Mochizuki, Sachi Moromizato, Katsuhiko Uesaka, Keiichi Fujiya, Shumpei Ohnami, Masanori Terashima, Takashi Sugino
Publikováno v:
Cancer Science
Mutually exclusive KIT and PDGFRA mutations are considered to be the earliest events in gastrointestinal stromal tumors (GIST), but insufficient for their malignant progression. Herein, we aimed to identify driver genes and signaling pathways relevan
Autor:
Ichiro Ito, Hideki Murata, Seiichi Hosaka, Ken Yamaguchi, Mitsuru Takahashi, Yukihiro Matsuyama, Koji Muramatsu, Tohru Mochizuki, Hirohisa Katagiri, Yuji Ishida, Yosuke Honda, Junji Wasa
Publikováno v:
International Journal of Clinical Oncology. 24:1468-1478
Pro-gastrin-releasing peptide (ProGRP) is an established tumor marker of small cell lung cancer. The purpose of this study was to determine if ProGRP could serve as a tumor marker for the Ewing sarcoma family of tumors (ESFTs). Sixteen patients with